Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence

Editorial

Jussi J Saukkonen et al. Am J Respir Crit Care Med. 2012.

. 2012 Mar 15;185(6):598-9.

doi: 10.1164/rccm.201112-2174ED.

No abstract available

Comment on

A comparison between two strategies for monitoring hepatic function during antituberculous therapy.
Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, George PM, Molyneaux PL, Cooke GS, Burroughs AK, Lalvani A, Wickremasinghe M, Kon OM. Singanayagam A, et al. Am J Respir Crit Care Med. 2012 Mar 15;185(6):653-9. doi: 10.1164/rccm.201105-0850OC. Epub 2011 Dec 28. Am J Respir Crit Care Med. 2012. PMID: 22198973

1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al.; Antituberculosis Therapy Subcommittee. An official ATS Statement: hepatotoxicity of antitiberculosis therapy. Am J Respir Crit Care Med 2006;174:935–952. - PubMed
1. Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 2011;6:e21836. - PMC - PubMed
1. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472–1477. - PubMed
1. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, Ballinger J, Swaden L, Johnson MA, Cropley I, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61:791–794. - PMC - PubMed
1. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, Elwood RK, Fitzgerald JM. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007;11:868–875. - PubMed